Bharat Biotech
Oct 06, 2020
MyoKardia buyout; Eidos acquisition; Amgen’s Aimovig; HCV discovery; Bharat Biotech’s Covaxin
MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree. BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
